Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia.

ABSTRACT:

Introduction

Acute myeloid leukemia (AML) is a type of blood cancer that is identified by the unrestricted growth of immature myeloid cells within the bone marrow. Despite therapeutic advances, AML prognosis remains highly variable, and there is a lack of biomarkers for customizing treatment. RNA N6-methyladenosine (m⁶A) modification is a reversible and dynamic process that plays a critical role in cancer progression and drug resistance.

Methods

To investigate the m⁶A modification patterns in AML and their potential clinical significance, we used the AUCell method to describe the m⁶A modification activity of cells in AML patients based on 23 m⁶A modification enzymes and further integrated with bulk RNA-seq data.

Results

We f

SUBMITTER: Li Z 

PROVIDER: S-EPMC10644381 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature